```
      (FILE 'HOME' ENTERED AT 13:42:42 ON 04 JUN 2007)

      FILE 'REGISTRY' ENTERED AT 13:42:56 ON 04 JUN 2007
L1              STRUCTURE UPLOADED
L2            7 S L1
L3          138 S L1 SSS FULL
L4            1 S CLITOCINE/CN

      FILE 'STNGUIDE' ENTERED AT 13:44:35 ON 04 JUN 2007

      FILE 'HCAPLUS' ENTERED AT 13:46:20 ON 04 JUN 2007
L5           83 S L3
L6           20 S L4
L7         2762 S (NONSENSE(W)MUTATION) OR (PREMATUIRE(W)STOP) OR (NONSENSE(W)S
L8        39081 S P53
L9            3 S L5 AND L7
L10           0 S L5 AND L8
L11           0 S L9 AND L10
L12           0 S L11 AND L6

      FILE 'STNGUIDE' ENTERED AT 13:46:29 ON 04 JUN 2007

      FILE 'HCAPLUS' ENTERED AT 13:47:12 ON 04 JUN 2007

      FILE 'STNGUIDE' ENTERED AT 13:47:12 ON 04 JUN 2007

      FILE 'HCAPLUS' ENTERED AT 13:51:49 ON 04 JUN 2007
L13      755413 S CANCER OR TUMOR OR NEOPLAS?
L14           5 S L5 AND L13
```

=> file registry
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 0.21 | 0.21

FILE 'REGISTRY' ENTERED AT 13:42:56 ON 04 JUN 2007

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 JUN 2007 HIGHEST RN 936470-74-5
DICTIONARY FILE UPDATES: 3 JUN 2007 HIGHEST RN 936470-74-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10625059exonucleo.str





chain nodes :
6 14 17 19 20 21 22 23 24 25 26 27 28 29 30
ring nodes :
1 2 3 4 5 7 8 9 10 11 12
chain bonds :
2-6 2-29 3-24 3-30 4-23 4-25 5-21 5-26 6-7 6-14 8-19 9-20 11-17 21-22
21-27 21-28
ring bonds :
1-2 1-5 2-3 3-4 4-5 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
1-2 1-5 2-3 2-6 2-29 3-4 3-24 3-30 4-5 4-23 4-25 5-21 5-26 6-7 6-14
7-8 7-12 8-9 8-19 9-10 9-20 10-11 11-12 11-17 21-22 21-27 21-28

G1:C,H

G2:C,N

G3:C,H,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 14:CLASS 17:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS
23:CLASS 24:CLASS
25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,H

G2 C,N

G3 C,H,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 13:43:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 250 TO ITERATE

100.0% PROCESSED 250 ITERATIONS 7 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 4052 TO 5948
PROJECTED ANSWERS: 7 TO 298

L2 7 SEA SSS SAM L1

=> d l2

L2 ANSWER 1 OF 7 REGISTRY COPYRIGHT 2007 ACS on STN

RN 909273-21-8 REGISTRY
ED Entered STN: 02 Oct 2006
CN Ribosylamine, N-(p-ethylphenyl)-, D- (5CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H19 N O4
SR CAS EARLY REGISTRATIONS
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l2 scan

L2 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN β-D-Xylofuranosylamine, N-(6-amino-5-nitro-4-pyrimidinyl)- (9CI)
MF C9 H13 N5 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L2 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN β-D-Lyxofuranosylamine, N-(4-methoxyphenyl)- (9CI)
MF C12 H17 N O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN β-L-Ribofuranosylamine, N-(6-amino-5-nitro-4-pyrimidinyl)- (9CI)
MF C9 H13 N5 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN α-D-Arabinofuranosylamine, N-(2-nitrophenyl)- (9CI)
MF C11 H14 N2 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s L1 sss full
FULL SEARCH INITIATED 13:44:16 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5282 TO ITERATE

100.0% PROCESSED 5282 ITERATIONS 138 ANSWERS

SEARCH TIME: 00.00.01

L3 138 SEA SSS FUL L1

=> s clitocine/cn
L4 1 CLITOCINE/CN

=> d l4

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 105798-74-1 REGISTRY
ED Entered STN: 21 Dec 1986
CN β-D-Ribofuranosylamine, N-(6-amino-5-nitro-4-pyrimidinyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Clitocine
FS STEREOSEARCH
MF C9 H13 N5 O6
CI COM
SR CA
LC STN Files: AGRICOLA, BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, DDFU, DRUGU, IPA, MEDLINE, NAPRALERT, PROUSDDR, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

20 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
20 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	181.85	182.06

FILE 'STNGUIDE' ENTERED AT 13:44:35 ON 04 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 4, 2007 (20070604/UP).

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.18	182.24

FILE 'HCAPLUS' ENTERED AT 13:46:20 ON 04 JUN 2007

FILE COVERS 1907 - 4 Jun 2007 VOL 146 ISS 24
FILE LAST UPDATED: 3 Jun 2007 (20070603/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> s l3

L5          83 L3

=> s l4

L6          20 L4

=> s (nonsense(w)mutation) or (prematuire(w)stop) or (nonsense(w)suppres?)

          8303 NONSENSE
        255449 MUTATION
          2377 NONSENSE(W)MUTATION
             0 PREMATUIRE
         42156 STOP
             0 PREMATUIRE(W)STOP
          8303 NONSENSE
        420273 SUPPRES?
           463 NONSENSE(W)SUPPRES?
L7         2762 (NONSENSE(W)MUTATION) OR (PREMATUIRE(W)STOP) OR (NONSENSE(W)SUPP
                RES?)

=> s p53

L8        39081 P53

=> s l5 and l7

L9          3 L5 AND L7

=> s l5 and l8

L10         0 L5 AND L8

=> s l9 and L10

L11         0 L9 AND L10

=> s l11 and l6

L12         0 L11 AND L6
```

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.60	184.84

FILE 'STNGUIDE' ENTERED AT 13:46:29 ON 04 JUN 2007

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 4, 2007 (20070604/UP).

=> d l9 1-3 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L9 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of nucleoside analogs for treating or preventing diseases associated with nonsense mutations of mRNA
GI



I



II

AB Nucleoside analogs I, wherein Z is (un)substituted alkyl, (un)substituted (un)substituted aryl, (un)substituted heteroaryl, (un)substituted cycloalkyl, (un)substituted heterocycle; X is CH, O, S, NH; R1 is H, (un)substituted alkyl, (un)substituted aryl, (un)substituted heteroaryl, (un)substituted cycloalkyl, (un)substituted heterocycle; R2 is (un)substituted alkyl, carboxy, amido, acyl, alkylcarbonyl, halogen, azide, alkyl amino, phosphate, phosphoester, alkyl ether; R3, R3', R4, R4' are independently (un)substituted ether, H, halogen, (un)substituted alkyl, (un)substituted (un)substituted aryl, (un)substituted heteroaryl, (un)substituted cycloalkyl, (un)substituted heterocycle are prepared for use in the treatment or prevention of diseases associated with nonsense mutations of mRNA. Thus, II was prepared and tested in a cell-based luciferase reporter assay containing a UGA premature termination codon that was stably transfected in 293T Human Embryonic Kidney cells (no data but very high potency and very high efficacy of protein synthesis). Further, I can be used as a prodrug in the treatment of autoimmune disease, blood diseases, collagen diseases, diabetes, neurodegenerative diseases, cardiovascular diseases, pulmonary diseases, inflammatory diseases, central nervous

system diseases.
AN 2006:740594 HCAPLUS <<LOGINID::20070604>>
DN 145:167496
TI Preparation of nucleoside analogs for treating or preventing diseases associated with nonsense mutations of mRNA
IN Wilde, Richard G.; Almstead, Neil G.; Welch, Ellen M.; Beckmann, Holger
PA USA
SO U.S. Pat. Appl. Publ., 47 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2006166926	A1	20060727	US 2005-48659	20050121
PRAI US 2005-48659		20050121		

OS MARPAT 145:167496

L9 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
AB The invention encompasses nucleoside compds., compns. comprising the compds. and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compds. or compns. Diseases that can be treated or prevented by compds. of the invention include, but are not limited to, cancer, autoimmune diseases, blood diseases, collagen diseases, diabetes, neurodegenerative diseases, cardiovascular diseases, pulmonary diseases, inflammatory diseases, lysosomal storage disease, tuberous sclerosis or central nervous system diseases. The present invention is based in part on the discovery of small mols. that modulate premature translation termination and/or nonsense-mediated mRNA decay.
AN 2004:80704 HCAPLUS <<LOGINID::20070604>>
DN 140:122839
TI Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
IN Wilde, Richard G.; Almstead, Neil G.; Welch, Ellen M.; Beckmann, Holger
PA PTC Therapeutics, Inc., USA; Tularik Inc.
SO PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004009610	A2	20040129	WO 2003-US23185	20030723
WO 2004009610	A3	20051006		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493816	A1	20040129	CA 2003-2493816	20030723
AU 2003261237	A1	20040209	AU 2003-261237	20030723
EP 1572709	A2	20050914	EP 2003-766015	20030723
EP 1572709	A3	20051123		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI US 2002-398334P	P	20020724		

WO 2003-US23185 W 20030723
OS MARPAT 140:122839

L9 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of nucleoside analogs and their use for treating cancer and diseases associated with somatic mutations of mRNA
GI



I



II

AB Nucleoside analogs I, where Z is alkyl, aryl, heteroaryl, cycloalkyl, heterocyclo, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, arylcarbonyl; X is CH, O, S or NH; R1 is hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, heterocyclo, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl; R2 is alkyl, carboxy, amido, acyl, alkylcarbonyl, halogen, bio-hydrolyzable group, OP(O)32-, O[P(O)3]23-, O[P(O)3]34-, N3, substitute aminomethyl, alkoxymethyl; R3, R3', R4 and R4' are independently alkoxy, hydrogen, halogen, alkyl, aryl, heteroaryl, cycloalkyl, heterocyclo, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, arylcarbonyl, alkylcarbonyl, a bio-hydrolyzable group, or R3 and R4 taken together form a bond, or together with the atoms to which they are attached form a heterocyclo, or R3 and R3' and/or R4 and R4' taken together with the carbon to which they are attached form C(O); were prepared for treating or preventing diseases associated with nonsense mutations of mRNA. Thus, nucleoside analog was prepared and tested in mice as antitumor agent. The present invention encompasses the in vitro or in vivo use of a compound of the invention, and the incorporation of a compound of the invention into pharmaceutical compns. and single unit dosage forms useful in the treatment and prevention of a variety of diseases and disorders. Specific diseases and disorders include those ameliorated by the suppression of a nonsense mutation in mRNA.
AN 2004:80703 HCAPLUS <<LOGINID::20070604>>
DN 140:128608
TI Preparation of nucleoside analogs and their use for treating cancer and diseases associated with somatic mutations of mRNA
IN Wilde, Richard G.; Kennedy, Paul D.; Almstead, Neil G.; Welch, Ellen M.; Takasugi, James J.; Friesen, Westley J.
PA PTC Therapeutics, Inc., USA
SO PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004009609	A2	20040129	WO 2003-US23184	20030723
	WO 2004009609	A3	20041021		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

```
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
            PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
            TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2004067900        A1    20040408    US 2003-625059         20030722
     CA 2493815           A1    20040129    CA 2003-2493815        20030723
     AU 2003254158        A1    20040209    AU 2003-254158         20030723
     EP 1534726           A2    20050601    EP 2003-766014         20030723
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRAI US 2002-398334P     P     20020724
     US 2003-625059      A     20030722
     WO 2003-US23184     W     20030723
OS   MARPAT 140:128608


=> d his

     (FILE 'HOME' ENTERED AT 13:42:42 ON 04 JUN 2007)

     FILE 'REGISTRY' ENTERED AT 13:42:56 ON 04 JUN 2007
L1             STRUCTURE UPLOADED
L2           7 S L1
L3         138 S L1 SSS FULL
L4           1 S CLITOCINE/CN

     FILE 'STNGUIDE' ENTERED AT 13:44:35 ON 04 JUN 2007

     FILE 'HCAPLUS' ENTERED AT 13:46:20 ON 04 JUN 2007
L5          83 S L3
L6          20 S L4
L7        2762 S (NONSENSE(W)MUTATION) OR (PREMATUIRE(W)STOP) OR (NONSENSE(W)S
L8       39081 S P53
L9           3 S L5 AND L7
L10          0 S L5 AND L8
L11          0 S L9 AND L10
L12          0 S L11 AND L6

     FILE 'STNGUIDE' ENTERED AT 13:46:29 ON 04 JUN 2007

     FILE 'HCAPLUS' ENTERED AT 13:47:12 ON 04 JUN 2007

     FILE 'STNGUIDE' ENTERED AT 13:47:12 ON 04 JUN 2007

=> log hold
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               0.06     196.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                               0.00      -2.34

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:47:28 ON 04 JUN 2007

Connecting via Winsock to STN
```

```
Welcome to STN International!  Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'STNGUIDE' AT 13:51:04 ON 04 JUN 2007
FILE 'STNGUIDE' ENTERED AT 13:51:04 ON 04 JUN 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.06     196.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -2.34

=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.12     196.11

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -2.34

FILE 'HCAPLUS' ENTERED AT 13:51:49 ON 04 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 4 Jun 2007  VOL 146 ISS 24
FILE LAST UPDATED: 3 Jun 2007  (20070603/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s cancer or tumor or neoplas?

        317251 CANCER
        409463 TUMOR
        495197 NEOPLAS?
L13     755413 CANCER OR TUMOR OR NEOPLAS?

=> s l5 and l13

L14           5 L5 AND L13
```

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.60	198.71

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.34

FILE 'STNGUIDE' ENTERED AT 13:51:52 ON 04 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 4, 2007 (20070604/UP).

=> d l14 1-5 ti
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L14 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN
TI In vivo antitumor activity of clitocine, an exocyclic amino nucleoside isolated from Lepista inversa

L14 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases

L14 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of nucleoside analogs and their use for treating cancer and diseases associated with somatic mutations of mRNA

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Synthesis of 3-deazaclitocine [2-amino-3-nitro-4(β-D-ribofuranosylamino)pyridine] as cytotoxic agent

L14 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Synthesis and intramolecular hydrogen bonding and biochemical studies of clitocine, a naturally occurring exocyclic amino nucleoside

=> d l14 1 2 4 5 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L14 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN
TI In vivo antitumor activity of clitocine, an exocyclic amino nucleoside isolated from Lepista inversa
AB A biol. guided fractionation from Lepista inversa (Scop.: Fr.) led to the isolation of clitocine, an exocyclic amino nucleoside. This compound and two mixts. of β/α anomers (mixture A, 40:60 and mixture B, 80:20) were synthesized or isolated depending on the purification procedure. The β anomer and clitocine mixts. A and B showed similar cytotoxic activities with IC50 values ranging from 20.5 to 42 nM in murine cancer cell lines (3LL and L1210) and from 185 to 578 nM in human cancer cell lines (DU145, K-562, MCF7, and U251). An in vivo study of mixture B was carried out on 3LL- and L1210-tumor-bearing mice. Clitocine solubilized in β-hydroxypropylcyclodextrin and injected at concns. of 0.5, 3, and 5 mg kg-1 did not significantly

increase the survival rate and lifespan of 3LL-tumor-bearing mice. In contrast, clitocine showed antitumor activity on L1210-tumor-bearing mice with a significant increase in lifespan and a decrease in the development of ascites observed at 3 mg kg-1. The induction of apoptosis may be the basis of the antitumor activity of clitocine against L1210 as suggested by flow-cytometry anal. of cells treated in vitro.

AN 2006:198073 HCAPLUS <<LOGINID::20070604>>
DN 144:266810
TI In vivo antitumor activity of clitocine, an exocyclic amino nucleoside isolated from Lepista inversa
AU Fortin, Helene; Tomasi, Sophie; Delcros, Jean-Guy; Bansard, Jean-Yves; Boustie, Joel
CS Institute de Chimie de Rennes Laboratoire de Pharmacognosie et de Mycologie EA "Substances Licheniques et Photoprotection", Universite Rennes 1, Rennes, 35043, Fr.
SO ChemMedChem (2006), 1(2), 189-196
CODEN: CHEMGX; ISSN: 1860-7179
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
AB The invention encompasses nucleoside compds., compns. comprising the compds. and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compds. or compns. Diseases that can be treated or prevented by compds. of the invention include, but are not limited to, cancer, autoimmune diseases, blood diseases, collagen diseases, diabetes, neurodegenerative diseases, cardiovascular diseases, pulmonary diseases, inflammatory diseases, lysosomal storage disease, tuberous sclerosis or central nervous system diseases. The present invention is based in part on the discovery of small mols. that modulate premature translation termination and/or nonsense-mediated mRNA decay.
AN 2004:80704 HCAPLUS <<LOGINID::20070604>>
DN 140:122839
TI Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
IN Wilde, Richard G.; Almstead, Neil G.; Welch, Ellen M.; Beckmann, Holger
PA PTC Therapeutics, Inc., USA; Tularik Inc.
SO PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004009610	A2	20040129	WO 2003-US23185	20030723
WO 2004009610	A3	20051006		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493816	A1	20040129	CA 2003-2493816	20030723

AU 2003261237	A1	20040209	AU 2003-261237	20030723
EP 1572709	A2	20050914	EP 2003-766015	20030723
EP 1572709	A3	20051123		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRAI US 2002-398334P P 20020724
WO 2003-US23185 W 20030723
OS MARPAT 140:122839

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Synthesis of 3-deazaclitocine [2-amino-3-nitro-4(β-D-ribofuranosylamino)pyridine] as cytotoxic agent
GI



AB Aminonitro(ribofuranosylamino)pyridine (I) was synthesized by glycosylation of 2,4-diamino-3-nitropyridine with 1-O-acetyl-2,3,5-tri-O-benzoyl-D-ribofuranose. Aminonitro(ribofuranosyl)pyridinimine II was also obtained. In vitro antitumor activity of I and II was evaluated.
AN 1991:536585 HCAPLUS <<LOGINID::20070604>>
DN 115:136585
TI Synthesis of 3-deazaclitocine [2-amino-3-nitro-4(β-D-ribofuranosylamino)pyridine] as cytotoxic agent
AU Franchetti, Palmarisa; Cappellacci, Loredana; Cristalli, Gloria; Grifantini, Mario; Vittori, Sauro
CS Dip. Sci. Chim., Univ. Camerino, Camerino, 62032, Italy
SO Nucleosides & Nucleotides (1991), 10(1-3), 543-5
CODEN: NUNUD5; ISSN: 0732-8311
DT Journal
LA English
OS CASREACT 115:136585

L14 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Synthesis and intramolecular hydrogen bonding and biochemical studies of clitocine, a naturally occurring exocyclic amino nucleoside
GI



I

AB The total synthesis of clitocine (I) recently isolated from Clitocybe inversa, has been accomplished. Glycosylation of 4,6-diamino-5-nitropyrimidine with 1-O-acetyl-2,3,5-tri-O-benzoyl-D-ribofuranose afforded the protected nucleoside exclusively as the β-anomer. Deprotection gave I containing <1% of its α-anomer. I inhibited L1210 cells in vitro with an ID50 of 3 + 10-8M. I was also a substrate and inhibitor of adenosine kinase with a Ki of 3 + 10-6M.

AN 1988:150899 HCAPLUS <<LOGINID::20070604>>
DN 108:150899

TI Synthesis and intramolecular hydrogen bonding and biochemical studies of clitocine, a naturally occurring exocyclic amino nucleoside

AU Moss, Randall J.; Petrie, Charles R.; Meyer, Rich B., Jr.; Nord, L. Dee; Willis, Randall C.; Smith, Roberts A.; Larson, Steven B.; Kini, Ganesh D.; Robins, Roland K.
CS Nucleic Acid Res. Inst., Costa Mesa, CA, 92626, USA

SO Journal of Medicinal Chemistry (1988), 31(4), 786-90
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 108:150899